A consortium led by the Danish biotech company, Adaptvac ApS, has received $12.4 million from CEPI (the Coalition for Epidemic Preparedness Innovations) and the EU to design and test a candidate vaccine that could offer broad protection against several filoviruses. Filoviruses are a family of viruses known to cause severe haemorrhagic fever in humans. The vaccine would be used to protect high risk populations, such as healthcare workers, in areas where filovirus outbreaks are most prevalent. These are primarily in Central and East Africa.
